報價延遲最少15分鐘:2024/04/30 01:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.42/-2.11
|
|
企業價值
8.62M
|
| 資產負債 |
|
每股賬面淨值
1.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
145.80K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/30 01:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |